Compare MXCT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | QNCX |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 167.0M |
| IPO Year | 2021 | 2019 |
| Metric | MXCT | QNCX |
|---|---|---|
| Price | $0.79 | $0.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | $7.50 | ★ $10.00 |
| AVG Volume (30 Days) | 935.8K | ★ 4.1M |
| Earning Date | 03-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,419,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $0.16 |
| 52 Week High | $4.67 | $4.55 |
| Indicator | MXCT | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 13.73 | 20.97 |
| Support Level | $1.19 | $2.92 |
| Resistance Level | $1.28 | $3.41 |
| Average True Range (ATR) | 0.09 | 0.45 |
| MACD | -0.04 | -0.36 |
| Stochastic Oscillator | 7.23 | 0.04 |
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.